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Abstract
Cancer‐related	 fatigue	 (CRF)	 is	 subjective	 and	has	wide	 inter‐individual	 variability.	
Given	that	leptin	is	commonly	associated	with	fatigue	syndrome,	its	use	as	a	potential	
biomarker	for	CRF	is	being	investigated.	The	primary	objective	of	this	study	was	to	
evaluate	 the	 association	between	 leptin	 and	CRF	 in	 early‐stage	breast	 cancer	 pa‐
tients	 receiving	 chemotherapy.	 In	 a	 prospective	 cohort	 study,	 patients	 completed	
assessments	at	baseline	(T1),	during	chemotherapy	(T2)	and	after	chemotherapy	(T3).	
Levels	of	plasma	leptin	and	adipokines	were	measured	using	a	Luminex	bead‐immu‐
noassay	 and	 CRF	 was	 measured	 using	 the	 Multi‐Dimensional	 Fatigue	 Symptom	
Inventory‐Short	Form	(MFSI‐SF).	Data	were	analysed	longitudinally	using	a	general‐
ised	 estimating	 equation	 incorporating	 clinically	 relevant	 parameters	 and	 
pro‐inflammatory	 adipokines.	 The	 analysis	 included	 136	 patients	 (mean	
age	±	SD	=	51.5	±	8.8	years;	 69.1%	 receiving	 anthracycline‐based	 chemotherapy).	
More	patients	experienced	CRF	at	T3	(23.8%)	than	at	T2	(13.8%)	compared	to	base‐
line.	An	increase	was	observed	in	the	median	plasma	leptin	level	at	T2,	followed	by	a	
decrease	at	T3	(T1:	4.07	ng/mL,	T2:	4.95	ng/mL	and	T3:	3.96	ng/mL).	In	the	multivari‐
ate	model,	the	change	in	leptin	levels	over	time	was	significantly	associated	with	the	
total	MFSI‐SF	 score	 (β	=	−0.15,	P	=	0.003)	 after	 adjusting	 for	 the	 tumour	 necrosis	
factor‐α	 (TNF‐α)	 level,	 anxiety,	 depression,	 insomnia,	 age,	 menopausal	 status	 and	
type	of	chemotherapy.	This	is	the	first	study	to	report	leptin	as	a	biomarker	that	pre‐
dicts	 the	 onset	 of	 CRF	 over	 time.	 Future	 studies	 are	 required	 to	 validate	 the	
findings.
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1  | INTRODUC TION
The	 estimated	 incidence	 of	 cancer‐related	 fatigue	 (CRF)	 has	 been	
reported	to	range	from	28%	to	91%	among	breast	cancer	patients,1 
depending	on	the	type	of	cancer,	treatment	modality	and	method	of	
assessment.	CRF	is	characterised	by	a	persistent	sense	of	tiredness	
that	may	be	related	to	cancer	and/or	cancer	treatment,	is	dispropor‐
tionate	 to	 recent	activity	and	 is	not	alleviated	by	 rest.2	 Left	unre‐
solved,	CRF	adds	on	to	patients’	distress	and	has	a	negative	impact	
on	their	quality	of	life.3
Given	 the	extent	of	 the	 impact	of	CRF	on	daily	 functioning,4 
addressing	 CRF	 should	 be	 an	 integral	 part	 of	 cancer‐supportive	
care.	 Nevertheless,	 this	 has	 proved	 challenging	 due	 to	 the	 lack	
of	an	objective	biomarker	to	monitor	these	symptoms.	The	expe‐
rience	 of	 fatigue	 is	 subjective	 in	 nature	 and	 has	wide	 inter‐indi‐
vidual	 variability	because	 some	patients	may	have	poor	physical	
functioning	and	impaired	performance	status	yet	will	not	complain	
of	fatigue,	and	vice	versa.	One	study	has	shown	that	pro‐inflam‐
matory	 cytokines	 could	 be	 potentially	 employed	 as	 biomarkers	
of	CRF	in	patients	with	advanced	cancer,5	and	that	changes	from	
baseline	 of	 selected	 biomarkers	 were	 associated	 with	 changes	
in	 patient‐reported	 outcome	 measures	 of	 appetite	 and	 fatigue.	
However,	the	circadian	variability	and	fluctuation	of	cytokine	lev‐
els	could	influence	the	outcomes	associated	with	the	biomarkers	
used	and	hinder	their	utility.6	Thus,	further	research	is	warranted	
to	determine	a	suitable	biomarker	for	monitoring	CRF	and	related	
symptoms	in	cancer	patients.
Leptin	is	an	endocrine	hormone	that	is	more	commonly	known	
for	its	metabolic	effects,	which	range	from	appetite	suppression	
to	 regulating	 body	 weight.7	 Leptin	 has	 shown	 moderate	 cor‐
relations	 to	 varying	 extents	 with	 fatigue	 in	 cohorts	 of	 patients	
with	 cardiovascular	 risk	 factors	 (r	=	0.22),8	 chronic	 fatigue	 syn‐
drome	(r	=	−0.51	to	0.73),6	chronic	hepatitis	C	infection	(r	=	0.25;	
r	=	0.30),9,10	and	irritable	bowel	syndrome	(r	=	0.60).11	In	another	
study,	 researchers	 found	 that	 plasma	 leptin	 levels	 could	 be	 in‐
duced	 by	 hydrocortisone,	 and	 were	 markedly	 increased	 in	 pa‐
tients	with	chronic	fatigue	syndrome.12	Hence,	we	hypothesized	
that	 leptin	 levels	may	 be	 positively	 correlated	with	 increases	 in	
fatigue	in	cancer	patients,	as	their	pro‐inflammatory	markers	are	
typically	elevated.
This	study	was	designed	to	investigate	the	association	between	
plasma	leptin	levels	and	CRF	in	a	cohort	of	early‐stage	breast	can‐
cer	patients,	 in	relation	with	other	relevant	clinical	factors	and	ad‐
ipokines.	Our	primary	objective	was	 to	assess	 leptin's	potential	 to	
function	as	a	biomarker	that	could	predict	the	onset	of	CRF.
2  | MATERIAL S AND METHODS
2.1 | Study design
This	 prospective	 cohort	 study	was	 conducted	 between	 2014	 and	
2017	 in	 Singapore.	 The	 study	 was	 approved	 by	 the	 Singhealth	
Institutional	 Review	 Board	 (CIRB	 2014/754/B),	 and	 written	 in‐
formed	consent	was	obtained	from	all	study	participants.
2.2 | Inclusion and exclusion criteria
The	 inclusion	 criteria	 were:	 (a)	 diagnosis	 with	 early	 stage	 (I‐III)	
breast	cancer;	 (b)	no	prior	history	of	chemotherapy	or	radiother‐
apy;	(c)	scheduled	to	receive	standard	adjuvant	chemotherapy;	(d)	
ambulatory	status	with	an	Eastern	Cooperative	Oncology	Group	
score	 of	 0	 or	 1;	 and	 (e)	 the	 ability	 to	 understand	 either	 English	
or	Chinese.	Patients	were	excluded	 if	 they	were	diagnosed	with	
metastatic	cancer,	had	another	medical	condition	that	precipitates	
fatigue	(such	as	severe	anemia	or	thyroid	dysfunction),	or	were	on	
medications	such	as	beta‐blockers	 that	might	precipitate	 fatigue	
as	a	side	effect.
2.3 | Study procedures
Patients	 were	 assessed	 at	 three	 time	 points:	 baseline	 before	
treatment	 initiation	 (T1),	 at	 least	 6	weeks	 after	 baseline	 during	
chemotherapy	 (T2),	 and	 at	 least	12	weeks	 after	 baseline	 after	 the	
completion	of	chemotherapy	 (T3).	Upon	recruitment,	patients’	de‐
mographic	 information	and	medication	 information	were	collected	
through	patient	interviews	and	electronic	databases.
2.4 | Study tools
At	each	time	point,	patients	completed	a	series	of	questionnaires	as‐
sessing	their	fatigue,	anxiety,	depression	and	health‐related	quality	
of	life	(HRQoL).	Both	English	and	Chinese	versions	of	all	study	tools	
were	available	and	administered	by	bilingual	interviewers.	The	dura‐
tion	to	complete	all	assessments	was	approximately	40	minutes.	The	
tools	included	the	following:
1.	 The	Multi‐dimensional	 Fatigue	 Symptom	 Inventory‐Short	 Form	
(MFSI‐SF)	 is	 questionnaire	 for	 measuring	 fatigue	 in	 cancer	 pa‐
tients.	 It	 consists	 of	 five	 subscales	with	 six	 items	each:	 general	
fatigue,	 physical	 fatigue,	 emotional	 fatigue,	 mental	 fatigue	 and	
vigour.	 Each	domain	 is	 rated	on	 a	 scale	 of	 0‐4.	 The	 total	 score	
is	 obtained	 by	 summing	 all	 the	 dimensions	 except	 the	 vigour	
domain	 which	 is	 subtracted.	 The	 total	 score	 ranges	 from	 −24	
to	96,	with	higher	scores	indicating	more	fatigue.	We	previously	
established	 the	 range	of	minimal	 clinically	 important	difference	
(MCID)	for	fatigue	worsening	as	4.50‐10.79.13	The	psychometric	
properties	 and	 measurement	 equivalence	 of	 the	 English	 and	
Chinese	versions	of	MFSI‐SF	have	been	demonstrated	in	breast	
cancer	 patients	 in	 Singapore.14
2.	 The	Beck	Anxiety	Inventory	(BAI)	is	a	validated	questionnaire	that	
measures	the	level	of	anxiety	in	patients.15	It	comprises	21	items	
in	which	patients	rate	their	somatic,	subjective	and	panic‐related	
aspects	of	anxiety	on	a	scale	of	0‐3.	The	summation	of	the	scores	
gives	 a	 total	 score	 ranging	 from	 0	 to	 63,	 with	 a	 higher	 score	
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indicating	a	greater	anxiety	 level.	Our	 research	 team	has	previ‐
ously	validated	the	psychometric	properties	and	language	equiva‐
lence	of	the	English	and	Chinese	versions	of	BAI.16
3.	 The	Beck	Depression	Inventory	(BDI)	is	a	validated	questionnaire	
that	 assesses	 the	 severity	 of	 depression17	 and	 had	 been	 previ‐
ously	used	by	our	team	on	breast	cancer	patients.18	There	are	21	
items	that	patients	rate	on	a	scale	of	0‐3.	The	summation	of	the	
scores	gives	a	total	score	ranging	from	0	to	63,	with	a	higher	score	
indicating	greater	severity	of	depression.
4.	 The	European	Organisation	for	Research	and	Treatment	of	Cancer	
Quality	 of	 Life	 Questionnaire	 (EORTC	 QLQ‐C30)	 assesses	
HRQoL.	This	tool	was	used	for	the	assessment	of	insomnia	in	pa‐
tients,	with	a	higher	score	on	the	symptom	scale	indicating	greater	
severity.	 Both	 the	 English	 and	 Chinese	 versions	 had	 been	 vali‐
dated	for	use	in	cancer	patients.19,20
2.5 | Quantification of plasma pro‐inflammatory 
adipokines and leptin levels
At	each	time	point,	10	ml	blood	samples	were	drawn	for	the	analysis	
of	pro‐inflammatory	adipokines	and	kept	in	an	ethylenediaminetet‐
raacetic	acid	(EDTA)	tube.	The	blood	was	centrifuged	at	1069	x	g	for	
10	minutes	within	40	minutes	of	collection	and	kept	frozen	at	−80°C	
until	 analysis.	 Levels	 of	 leptin	 were	 quantified	 using	 the	 Human	
Cancer	Biomarker	Panel	(Biorad,	CA,	USA)	while	the	levels	of	IL‐6,	
IL‐8	and	tumour	necrosis	factor‐α	(TNF‐α)	were	quantified	using	the	
Multiplex	immunoassay	(Luminex™)	according	to	the	manufacturer's	
instructions.	IL‐6,	IL‐8	and	TNF‐α	are	other	known	pro‐inflammatory	
adipokines21‐23	that	were	quantified	so	that	their	relationships	with	
leptin	and	fatigue	could	be	controlled	in	the	analysis.	Each	analysis	
was	conducted	in	duplicate,	with	an	intra‐assay	coefficient	of	varia‐
tion	of	≤10%	being	considered	acceptable.24
2.6 | Statistical analysis
Patients’	 demographic	 information,	 clinical	 characteristics	 at	 base‐
line	and	the	proportions	of	patients	with	CRF	were	summarised	using	
descriptive	 statistics.	 The	 Friedman	 test	 was	 used	 to	 analyse	 the	
changes	in	plasma	adipokines	and	leptin	over	the	various	time	points,	
and	post	hoc	Wilcoxon	signed‐rank	test	was	used	to	identify	the	time	
points	at	which	a	change	was	observed.	Spearman's	rank	correlation	
coefficient	was	used	to	examine	the	relationship	between	each	vari‐
able	and	leptin	at	each	time	point.	Spearman's	rank	correlation	was	
also	 used	 to	 determine	 the	 association	 between	 continuous	 vari‐
ables	of	interest	and	total	MFSI‐SF	score.	The	Mann‐Whitney	U	test	
was	used	to	compare	fatigue	levels	between	groups	for	categorical	
variables.
The	 longitudinal	 association	of	CRF	with	plasma	 leptin	 and	 ad‐
ipokine	 levels	was	assessed	using	 the	generalised	estimating	equa‐
tion	model.	The	correlation	structure	with	the	smallest	criterion	was	
chosen	using	the	quasi‐likelihood	under	the	independence	model	cri‐
terion.	Leptin	was	first	analysed	as	a	single	variable.	Next,	the	follow‐
ing	known	confounders	 that	affect	CRF	were	analysed	 individually	
against	 total	MFSI‐score	 across	 the	 time	points:	 anxiety,25	 depres‐
sion,25	insomnia,26	menopausal	status,27	anaemia	status,28	body	mass	
index	(BMI),29	age,30	type	of	chemotherapy,31	and	pro‐inflammatory	
adipokines	such	as	IL‐6,	IL‐8	and	TNF‐α.21‐23	Confounders	with	P‐val‐
ues	<0.05	were	considered	to	be	statistically	significant	and	included	
in	the	final	model	as	covariates	to	examine	plasma	leptin	levels	with	
respect	to	fatigue	levels.	All	statistical	analyses	were	conducted	with	
STATA	 version	 15	 (Statacorp,	 TX,	 2017),	 and	 two‐sided	 P‐values	
<0.05	were	considered	statistically	significant.
3  | RESULTS
3.1 | Patient demographics
A	 total	 of	 136	 early‐stage	 breast	 cancer	 patients	 were	 included	
in	 this	 analysis,	 and	 their	 demographics	 are	 summarised	 in	
TA B L E  1  Baseline	demographics	and	clinical	characteristics	of	
patents	(n	=	136)
Demographic information
Mean ± SD or 
Frequency (%)
Age	(years) 51.5	±	8.8
BMI	(kg/m2) 23.9	±	4.1
Ethnicity
Chinese 112	(82.4)	
Malay 12	(8.8)	
Indian 7	(5.2)	
Othersa  5	(3.7)	
Breast	cancer	stage
I 15	(11.0)	
II 92	(67.7)	
III 29	(21.3)	
ECOG	Performance	Status
0 132	(97.1)	
1 4	(2.9)	
Baseline	Haemoglobin	levels
<12	g/dL 35	(25.7)	
>12	g/dL 101	(74.3)	
Menopausal	status
Premenopausal 69	(50.7)	
Postmenopausal 67	(49.3)	
Chemotherapy	Regimen
Anthracycline‐based 94	(69.1)	
Non‐anthracycline‐based 42	(30.9)	
Baseline	anxiety	(BAI	total	score)b  7.25	±	7.86
Baseline	depression	(BDI	total	score)c  6.48	±	7.98
Baseline	insomnia	scored  22.3	±	26.9
Abbreviation:	ECOG	as	Eastern	Cooperative	Oncology	Group.
aOthers	include:	4	Filipinos	and	1	Sikh.	
bBAI	total	score	is	63	points.	
cBDI	total	score	is	63	points.	
dInsomnia	subscale	total	score	is	100	points.	
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Table	 1.	 The	 mean	 age	±	standard	 deviation	 (SD)	 of	 the	 patients	
was	51.5	±	8.8	years,	and	the	mean	BMI	±	SD	was	23.9	±	4.1	kg/m2. 
Majority	of	the	patients	were	Chinese	(82.4%),	had	been	diagnosed	
with	stage	II	breast	cancer	(67.7%)	and	received	anthracycline‐based	
chemotherapy	(69.1%).
3.2 | Prevalence of cancer‐related fatigue
Using	the	MCID	as	a	cut‐off,	patients	who	experienced	a	deteriora‐
tion	of	≥11	points	from	baseline	were	considered	as	fatigue	cases.	A	
total	of	23.8%	of	patients	experienced	CRF	at	T3	compared	to	13.8%	
of	patients	at	T2,	using	the	baseline	as	a	reference.	The	overall	inci‐
dence	of	CRF	from	T1	to	T3	was	24.6%.
3.3 | Plasma levels of adipokines and leptin across 
time points
The	 plasma	 levels	 of	 the	 individual	 adipokines	 are	 summarised	 as	
the	medians	with	the	interquartile	ranges	(Table	2).	There	were	sta‐
tistically	significant	changes	in	the	plasma	levels	of	leptin,	IL‐6,	Il‐8	
and	TNF‐α	 across	 the	 three	 time	points	 (P‐value	<0.001	using	 the	
Friedman	test).	Compared	to	baseline,	a	median	increase	of	plasma	
leptin	levels	was	observed	at	T2,	followed	by	a	decrease	at	T3	(T1:	
4.07	ng/mL,	T2:	4.95	ng/mL	and	T3:	3.96	ng/mL).	For	IL‐6,	there	was	
an	 increase	 in	 plasma	 levels	 towards	 the	 end	 of	 chemotherapy	 at	
T3	(T1:	0.80	pg/mL,	T2:	1.11	pg/mL,	T3:	1.27	pg/mL).	For	IL‐8,	there	
was	 a	 decrease	 in	 plasma	 levels	 at	 T2,	 followed	by	 an	 increase	 at	
TA B L E  2  Comparison	of	plasma	adipokine	and	leptin	levels	across	the	time	points
Biomarker
Plasma adipokine concentration in Median (Inter‐quartile 
range) Friedman Test
Post‐hoc analysis: Wilcoxon sign 
rank test
T1 T2 T3 P‐value T1‐T2 T1‐T3 T2‐T3
Leptin	(ng/mL)	 4.07	(2.96,	6.61)	 4.95	(3.27,	7.16)	 3.96	(2.68,	6.07)	 <0.001 <0.001 0.56 <0.001
IL‐6	(pg/mL)	 0.80	(0.36,	1.72)	 1.11	(0.57,	2.46)	 1.27	(0.53,	2.60)	 <0.001 <0.001 <0.001 0.07
IL‐8	(pg/mL)	 3.70	(2.29,	4.95)	 3.33	(2.25,	5.06)	 3.69	(2.48,	5.28)	 <0.001 0.42 0.04 <0.001
TNF‐α	(pg/mL)	 6.41	(2.76,	15.15)	 6.95	(3.22,	18.61)	 8.27	(2.71,	19.71)	 <0.001 0.78 <0.001 <0.001
Abbreviation:	TNF‐α,	tumour	necrosis	factor‐α.
Bolded	are	P‐values	<	0.05	and	P‐values	for	post‐hoc	analysis	cut‐off	=	0.0167.
In	cases	for	patients	whose	plasma	levels	of	adipokine	were	below	the	detection	limit,	the	laboratory	values	are	treated	as	missing	values	in	the	
statistical	analysis.
TA B L E  3  Correlation	of	plasma	adipokine	levels	and	known	confounders	against	leptin	at	individual	time	points	(T1,	T2	and	T3)
T1 T2 T3
r P‐value r P ‐value r P ‐value
IL‐6 0.14 0.18 0.07 0.50 0.07 0.52
IL‐8 0.20 0.02 0.06 0.46 0.06 0.46
TNF‐α −0.03 0.71 −0.07 0.44 −0.02 0.85
Anxiety −0.09 0.29 −0.03 0.70 0.008 0.92
Depression −0.20 0.02 −0.25 <0.001 −0.08 0.37
Insomnia −0.07 0.43 −0.02 0.83 −0.20 0.02
Body	mass	index 0.59 <0.001 0.56 <0.001 0.58 <0.001
Age 0.23 <0.001 0.15 0.08 0.16 0.07
Categorical variables
T1 T2 T3
z‐score P ‐value z‐score P ‐value z‐score P ‐value
Menopausal	status −3.14 0.002 −1.87 0.06 −2.51 0.01
Anaemia	status −0.54 0.59 2.34 0.02 −0.46 0.64
Type	of	chemotherapy 0.44 0.66 −2.14 0.03 1.54 0.12
Abbreviation:	TNF‐α,	tumour	necrosis	factor‐α.
Bolded	are	P‐values	<	0.05.
For	continuous	variables,	data	is	presented	as	spearman	correlation	coefficients	with	r	and	its	P‐values.	For	categorical	variables,	data	is	presented	as	
the	test	statistic	(z)	along	with	p‐values	of	Mann‐Whitney	U	tests	used	to	compare	the	proportion.
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T3	 (T1:	 3.70	pg/mL,	 T2:	 3.33	pg/mL,	 T3:	 3.69	pg/mL).	 For	 TNF‐α,	
there	was	a	sustained	increase	in	plasma	levels	(T1:	6.41	pg/mL,	T2:	
6.95	pg/mL,	T3:	8.27	pg/mL).
3.4 | Correlation of plasma adipokines levels and 
confounders against plasma leptin levels at individual 
time points
Considering	 relationships	 between	 leptin	 and	 each	 individual	 adi‐
pokine,	 only	 IL‐8	 had	 a	 statistically	 significant	 correlation	 at	 T1	
(r	=	0.20,	P	=	0.02).	At	T1,	there	were	no	significant	correlations	be‐
tween	leptin	and	IL‐6	or	TNF‐α.	At	T2	and	T3,	none	of	the	adipokines	
showed	statistically	significant	correlations	with	leptin	(Table	3).
Among	the	confounders,	leptin	was	positively	correlated	with	BMI	
across	all	time	points	(T1:	r	=	0.59,	T2:	r	=	0.56,	T3:	r	=	0.58,	all	P‐values	
<0.001)	and	with	age	at	T1	(r	=	0.23,	P	<	0.001).	There	was	a	significant	
negative	correlation	between	plasma	leptin	levels	and	depression	at	T1	
and	T2	(r	=	−0.20,	P	=	0.02	and	r	=	−0.25,	P	<	0.001,	respectively)	and	
with	insomnia	at	T3	(r	=	−0.20,	P	=	0.02).	Among	categorical	variables,	
there	was	a	difference	in	plasma	leptin	levels	for	menopausal	status	at	
T1	and	T3	(P	=	0.002	and	0.01	respectively),	for	anaemia	status	at	T2	
(P	=	0.02)	and	the	type	of	chemotherapy	at	T2	(P	=	0.03).
3.5 | Correlation of plasma adipokines levels, known 
confounders and leptin against fatigue levels across 
time points (T1‐T3)
There	 were	 consistent	 strong	 correlations	 with	 fatigue	 levels	
across	 all	 time	points	 for	 anxiety,	 depression	 and	 insomnia.	Age	
was	 negatively	 correlated	with	CRF	 across	 time	 points	 and	CRF	
level	 also	 differed	 for	 the	 type	 of	 chemotherapy.	 There	 was	
only	a	significant	negative	correlation	at	T1	for	 leptin	 (r	=	−0.25,	
P	=	0.005)	(Table	4).
Across	T1	to	T3,	leptin	was	negatively	correlated	with	the	total	
MFSI‐SF	 score	 (β =	−0.56,	P	<	0.001),	with	 every	 1	 unit	 decrease	
of	 leptin	 being	 associated	 with	 a	 0.56	 increase	 in	 total	MFSI‐SF	
score	(Table	2).	TNF‐α	was	also	inversely	correlated	with	the	total	
MFSI‐SF	 score	 (β =	−0.02,	P	=	0.003).	 IL‐6	 and	 IL‐8	 did	 not	 show	
a	statistically	significant	correlation	with	total	MFSI‐SF	score.	For	
other	individual	explanatory	variables,	there	were	statistically	sig‐
nificant	positive	associations	for	anxiety	(β	=	1.38,	P	<	0.001),	de‐
pression	 (β	=	1.85,	 P	<	0.001)	 and	 insomnia	 (β	=	0.15,	 P	<	0.001)	
and	 significant	 negative	 correlations	 with	 menopausal	 status	
(β	=	−5.59,	P	=	0.04),	age	(β =	−0.57,	P	<	0.001)	and	type	of	chemo‐
therapy	(β	=	−10.65,	P	<	0.001).	Anaemia	status	(β	=	0.02,	P	=	0.09)	
and	BMI	(β =	−0.39,	P	=	0.13)	were	not	significantly	correlated	with	
total	MFSI‐SF	score.
3.6 | Adjusted model showing an association 
between leptin and CRF
Using	 P‐values	 <0.05	 as	 selection	 criteria,	 the	 variables	 with	 sta‐
tistically	 significant	 associations	 with	 CRF	 were	 TNF‐α,	 anxiety,	
depression,	 insomnia,	 age,	menopausal	 status	and	 type	of	 chemo‐
therapy.	 These	 variables	 were	 included	 as	 covariates	 in	 the	 final	
model.	 Results	 showed	 that	 leptin	 remained	 inversely	 associated	
with	 total	 MFSI‐SF	 score	 but	 the	 beta‐coefficient	 for	 leptin	 with	
the	MFSI‐score	was	attenuated	(β =	−0.15,	P	=	0.003),	with	every	1	
TA B L E  4  Correlation	of	plasma	adipokine	levels,	known	confounders	and	leptin	against	fatigue	levels	across	time	points	(T1‐T3)
T1 T2 T3 T1‐T3
r P‐value r P‐value r P‐value β (SE) P‐value
Leptin −0.25 0.005 −0.11 0.22 0.02 0.83 −0.56 (0.13) <0.001
IL‐6 0.007 0.94 0.17 0.10 0.09 0.36 0.50	(0.46)	 0.27
IL‐8 −0.07 0.45 −0.004 0.96 0.04 0.65 0.10	(0.38)	 0.12
TNF‐α 0.05 0.57 0.001 0.99 0.05 0.58 −0.02 (0.004) 0.003
Anxiety 0.65 <0.001 0.63 <0.001 0.68 <0.001 1.38 (0.13) <0.001
Depression 0.74 <0.001 0.74 <0.001 0.75 <0.001 1.85 (0.14) <0.001
Insomnia 0.30 <0.001 0.34 <0.001 0.44 <0.001 0.15 (0.03) <0.001
Body	mass	index −0.17 0.054 −0.05 0.59 −0.04 0.78 −0.39	(0.26)	 0.13
Age −0.34 <0.001 −0.27 0.002 −0.25 0.004 −0.57 (0.12) <0.001
Categorical variables
T1 T2 T3 T1‐T3
z‐score P‐value z‐score P‐value z‐score P‐value β (SE) P‐value
Menopausal	status 1.78 0.08 1.11 0.27 1.49 0.14 −5.59 (2.64) 0.04
Anaemia	status −0.73 0.47 −0.43 0.67 2.06 0.04 0.02	(0.01)	 0.09
Type	of	
chemotherapy
3.32 <0.001 3.57 <0.001 3.50 <0.001 −10.65 (2.32) <0.001
Abbreviation:	TNF‐α,	tumour	necrosis	factor‐α.
Bolded	are	p‐values	<	0.05.
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unit	decrease	of	leptin	being	associated	with	a	0.14	increase	in	total	
MFSI‐SF	score	across	time	points	(Table	5).
While	leptin	was	originally	associated	with	the	general	(β =	−0.16,	
P	<	0.001),	emotional	(β	=	−0.11,	P	<	0.001)	and	mental	sub‐domains	
(β	=	−0.06,	P	=	0.025)	of	MFSI‐SF	scale,	the	beta	coefficients	of	the	
respective	 five	 sub‐domains	 scores	 were	 not	 statistically	 signifi‐
cant	in	the	final	model	(Table	6).	In	the	analysis	of	other	explanatory	
variables	 in	 the	 final	 model,	 there	 were	 positive	 significant	 asso‐
ciations	with	CRF	 for	 anxiety	 (β	=	0.74,	P	<	0.001)	 and	 depression	
(β	=	1.06,	P	<	0.001)	and	significant	negative	associations	for	TNF‐α 
(β =	−0.009,	P	<	0.001)	and	age	(β	=	−0.23,	P	=	0.004).
4  | DISCUSSION
In	 our	 cohort	 of	 early‐stage	 breast	 cancer	 patients,	 plasma	 leptin	
levels	were	found	to	be	significantly	and	negatively	correlated	with	
total	MFSI‐SF	score	across	time	points	(β	=	−0.56,	P	<	0.01).	This	re‐
lationship	remained	significant	(β	=	−0.15,	P	=	0.003)	even	after	ad‐
justing	for	the	statistically	significant	covariates	in	our	final	model.	
This	result	does	not	support	our	initial	hypothesis,	in	which	we	pre‐
dicted	that	leptin	levels	would	be	positively	correlated	with	fatigue	
levels,	as	observed	in	patient	cohorts	of	other	disease	states.6,8,9
The	difference	in	direction	observed	for	the	effect	of	leptin	on	
fatigue	suggests	that	the	experience	of	CRF	may	be	different	from	
fatigue‐associated	 processes	 in	 other	 disease	 states.	 The	 posi‐
tive	correlations	between	fatigue	and	adipokines	had	been	mostly	
observed	 in	 patients	 with	 other	 conditions	 marked	 by	 inflamma‐
tion.6,9,10	 For	 instance,	 in	 a	 cohort	 of	 patients	with	 cardiovascular	
risk	 factors,	 plasma	 leptin	 levels	 were	 significantly	 and	 positively	
associated	with	 fatigue	 score	 (r	=	0.22,	P	<	0.001)	 and	 retained	 an	
independent	 association	 in	 a	 multiple	 logistic	 regression.8	 Yet	 in	
another	 study	 evaluating	 patients	 with	 systemic	 lupus	 erythema‐
tosus,	there	was	no	significant	association	between	adipokines	and	
fatigue	levels,	but	their	correlation	was	reported	to	be	negative.	In	
that	model,	 after	adjustment	 for	age,	 sex,	 race/ethnicity	and	BMI,	
leptin	was	negatively	correlated	with	fatigue	levels,	measured	using	
the	Fatigue	Severity	Scale	(β	=	−0.12,	P	=	0.61)	and	patient‐reported	
fatigue	scores	(β	=	−0.066,	P	=	0.96).	The	correlations	between	ad‐
ipokines	 and	 both	 physical	 activity	 and	 disease	 activity	 were	 ex‐
plained	by	differences	in	BMI.32
These	 observed	 differences	 in	 CRF	may	 also	 be	 nuanced	 and	
subjected	to	changes	that	depend	on	the	individual	sub‐domains	of	
CRF	being	examined.	While	CRF	is	a	multidimensional	construct,	it	
is	possible	that	not	all	facets	of	fatigue	are	equally	associated	with	
changes	in	adipokine	levels.	This	is	supported	by	our	results	in	which	
plasma	 leptin	 levels	were	significantly	correlated	with	 the	sub‐do‐
mains	of	general,	emotional	and	mental	fatigue	but	not	the	physical	
and	vigour	sub‐domains.	In	the	final	model,	leptin	was	significantly	
correlated	with	only	the	total	MFSI‐SF	scores	but	not	the	remaining	
sub‐domains.	This	reinforces	the	need	for	studies	to	study	the	spe‐
cific	domains	of	fatigue	more	closely.
With	 regard	 to	 individual	 subdomains	 of	 fatigue,	 anxiety	 and	
depression	continued	to	be	strong	predictors	of	fatigue	levels	over	
time,	showing	significant	correlations	with	all	five	sub‐domains.	This	
observation	was	also	reported	in	a	separate	cohort	of	breast	cancer	
survivors,	 in	which	 the	 research	 team	reported	 that	patients	diag‐
nosed	with	 depression	 and	 anxiety	 before	 chemotherapy	were	 at	
higher	risk	of	fatigue	onset	at	a	later	period.3	This	finding	suggests	
that	some	psychological	symptoms	may	form	a	fairly	stable	symp‐
tom	 cluster	with	CRF.	 It	 also	 supports	 the	 possibility	 that	 anxiety	
and	depression	add	to	the	stress	response	and	weaken	the	immune	
system,	triggering	inflammatory	mediators	involved	in	CRF	and	lead‐
ing	to	pro‐inflammatory	changes	 in	 the	body.33	These	findings	are	
aligned	with	reviews	reporting	depression	and	anxiety	as	prominent	
correlates	 of	 CRF,	 25,33,34	 and	 lend	 strength	 to	 the	 argument	 that	
psychological	distress	needs	to	be	accounted	for	when	investigating	
the	usefulness	of	leptin	as	a	biomarker	for	CRF.
Based	on	our	findings,	it	would	be	interesting	to	explore	the	re‐
lationships	between	leptin	and	other	pro‐inflammatory	biomarkers.	
Various	cytokines	such	as	TNF‐α,	IL‐6	and	IL‐1	can	induce	metabolic	
changes	by	mimicking	the	action	of	neuropeptides	such	as	leptin	be‐
cause	of	their	structural	similarity.35	A	decrease	in	food	intake	would	
usually	suppress	leptin	expression,	but	in	the	presence	of	some	cy‐
tokines,	plasma	leptin	levels	can	be	increased	and	work	against	the	
normal	 compensatory	mechanisms	 set	 in	 place	 for	 leptin	 levels	 to	
regulate	appetite.	A	possible	explanation	for	the	decrease	in	leptin	
levels	with	higher	fatigue	levels	could	be	that	an	adaptive	reduction	
of	energy	expenditure	has	been	induced,	resulting	in	increased	ap‐
petite	 in	 response	 to	metabolic	 impairment	 induced	by	 cancer‐re‐
lated	inflammation.	It	might	also	be	more	meaningful	to	evaluate	the	
ratio	of	plasma	leptin	to	other	known	pro‐inflammatory	cytokines	to	
interpret	inflammatory	status,	especially	if	they	work	as	a	network	
and	 if	 their	 levels	 affect	 each	 other.	 In	 the	 pathogenesis	 of	 some	
autoimmune	diseases,	 leptin	has	been	characterised	together	with	
adiponectin	and	resistin.32,36	In	an	ovarian	cancer	study,	pro‐inflam‐
matory	cytokines	such	as	IL‐6	and	TNF‐α	were	reported	to	 induce	
an	acute‐phase	protein	response	that	contributed	to	altered	energy	
TA B L E  5  Association	of	plasma	leptin	levels	against	total	
MFSI‐SF	score	after	adjusting	for	statistically	significant	covariates
Variable
Total MFSI‐SF score
Coefficient β (SE) P‐value
Constant 19.80 (3.39) <0.001
Adjusted	Leptin(ng/mL)	 −0.15 (0.05) 0.003
TNF−α(pg/mL)	 −0.009 (0.002) <0.001
Anxiety 0.74 (0.14) <0.001
Depression 1.06 (0.17) <0.001
Insomnia −0.002	(0.02)	 0.94
Age −0.23 (0.08) 0.004
Menopausal	status 2.10	(1.50)	 0.16
Type	of	chemotherapy −1.75	(0.94)	 0.06
Abbreviation:	TNF‐α,	tumour	necrosis	factor‐α.
Bolded	are	P‐values	<	0.05.
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metabolism,	 which	 regulated	 leptin	 levels.29	 In	 another	 cohort	 of	
lung	cancer	patients,37	the	research	team	found	significant	positive	
associations	among	plasma	levels	of	TNF‐α,	IL‐1	and	CRF.	Together,	
these	studies	and	our	results	suggest	that	leptin	should	be	included	
in	studies	in	which	relationships	between	fatigue	and	cytokines	are	
explored.
One	strength	of	this	study	was	the	use	of	a	longitudinal	study	
design	with	repeated	measurements	of	outcomes	at	various	time	
points,	 which	 allowed	 us	 to	 determine	 whether	 a	 decrease	 in	
leptin	levels	signalled	a	rise	in	the	fatigue	experienced	by	breast	
cancer	patients	at	a	separate	time	point.	Most	of	the	current	fa‐
tigue	studies	have	been	cross‐sectional	so	far,8,9	and	are	not	able	
to	 track	 the	 trajectories	 between	 fatigue	 and	 other	 variables,	
given	how	some	of	the	other	symptoms	may	be	transient.	A	limita‐
tion	of	this	study	lies	in	that	there	were	no	cancer	control	patients	
who	did	not	undergo	chemotherapy	 to	provide	a	 comparison	of	
CRF	experience.
Understanding	 the	 role	of	 leptin	 in	 relation	 to	CRF	may	help	
us	to	devise	more	tailored	 interventions	such	as	exercise	to	mit‐
igate	CRF	 in	 the	future.	 In	a	 randomised	controlled	trial	examin‐
ing	 the	effects	of	exercise	 in	overweight	or	obese	breast	cancer	
survivors,38	circulating	biomarkers	(insulin,	IGF‐1,	adiponectin	and	
leptin)	were	significantly	improved	post‐intervention,	compared	to	
usual	care.	In	another	trial,	a	decrease	in	leptin	concentrations	in	
breast	cancer	survivors	who	exercised	compared	to	controls	was	
reported.39
Several	concerns	need	to	be	addressed	before	any	potential	fa‐
tigue	 biomarker	 can	 have	 clinical	 utility.	 The	 observed	 difference	
in	direction	for	effect	of	leptin	on	fatigue	may	be	partly	attributed	
to	 the	non‐specific	 nature	of	 fatigue,	which	 can	be	 challenging	 to	
quantify	despite	use	of	validated	questionnaires	and	 is	dependent	
on	 the	 study	 tools	 used.	 There	 is	 no	 consistent	 definition	 of	 CRF	
and	a	general	 lack	of	agreement	about	which	biomarkers	 to	study	
or	how	to	collect	and	test	them.	Research	aimed	at	resolving	these	
issues	would	help	to	advance	the	understanding	of	the	mechanisms	
that	underpin	CRF	and	could	improve	the	quality	of	life	of	individuals	
who	experience	it.
In	 conclusion,	 our	 data	 show	 that	 there	 is	 an	 inverse	 correla‐
tion	 between	 plasma	 leptin	 levels	 and	 fatigue	 levels	 over	 time	 in	
early‐stage	 breast	 cancer	 patients	 undergoing	 chemotherapy.	 The	
association	with	 total	 score	 remained	 statistically	 significant	 after	
adjusting	for	known	confounders	of	CRF,	enabling	leptin	to	function	
as	a	biomarker	that	could	predict	onset	of	CRF.
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